Physician profile
Cuong Ton
NPI 1508259730
$3,723.35
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $339 · 2021: $1,077 · 2022: $1,184 · 2023: $1,123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,123.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $670.91 | 2019-2023 | Rexulti, Abilify Maintena, Nuedexta |
| Abbvie INC. | $605.02 | 2021-2023 | Vraylar |
| Neurocrine Biosciences, INC. | $533.01 | 2019-2023 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $374.54 | 2021-2023 | |
| Vanda Pharmaceuticals INC. | $303.95 | 2021-2023 | Hetlioz, Fanapt |
| Idorsia Pharmaceuticals US INC | $259.14 | 2022-2023 | Quviviq |
| Eisai INC. | $193.41 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $189.67 | 2021-2022 | |
| Corium, LLC | $133.94 | 2022-2023 | Azstarys |
| Alkermes, INC. | $130.04 | 2021-2023 | Aristada, Lybalvi |
| Avanir Pharmaceuticals, INC. | $57.20 | 2021-2022 | |
| Tris Pharma INC | $39.05 | 2023 | Dyanavel Xr |
| Neos Therapeutics, Lp | $37.67 | 2022-2023 | Adzenys Xr-Odt |
| Alfasigma USA, INC. | $34.37 | 2021 | |
| Axsome Therapeutics, INC. | $33.13 | 2023 | Auvelity |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $32.31 | 2022 | |
| Almatica Pharma LLC | $22.20 | 2023 | Gralise |
| Owp Pharmaceuticals, INC. | $20.96 | 2021 | |
| Lilly USA, LLC | $20.01 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.34 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cuong Ton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.